CK Life Sciences Deepens R&D Pivot as 2025 Loss Widens on Investment and One-Offs

An update from CK Life Sciences International (Holdings), Inc. ( (HK:0775) ) is now available.

CK Life Sciences reported a loss attributable to shareholders of HK$186.8 million for 2025, driven by higher R&D spending and non-cash extraordinary items, despite stronger profits from its commercial businesses. Excluding one-off effects, net profit from commercial operations rose to HK$130.8 million, but the board did not recommend a final dividend for the year.

The company underwent a major reorganisation to intensify pharmaceuticals and diagnostics R&D, spinning key assets into Nasdaq-listed partners and a new cancer vaccines unit. Transactions with TransCode Therapeutics for melanoma vaccine seviprotimut-L and Dogwood Therapeutics for Halneuron®, plus the creation of Sequencio Therapeutics and a new Scientific Advisory Board, are designed to strengthen execution, diversify the pipeline and improve access to biotech funding, particularly in the U.S. market.

The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.

More about CK Life Sciences International (Holdings), Inc.

CK Life Sciences International (Holdings) Inc. is a biotechnology company focused on pharmaceuticals and diagnostics, with an emphasis on cancer vaccines and pain therapeutics. The group operates through commercial businesses and R&D platforms, targeting substantial unmet medical needs in oncology and non-opioid pain management, and increasingly leverages U.S. biotech and capital markets for funding and development.

Average Trading Volume: 7,584,959

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.59B

Learn more about 0775 stock on TipRanks’ Stock Analysis page.